Skip to main content
Erschienen in: Drugs 6/2006

01.04.2006 | Adis Drug Profile

Sumatriptan Fast-Disintegrating/Rapid-Release Tablets

verfasst von: Marit D. Moen, Gillian M. Keating

Erschienen in: Drugs | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

▴ Sumatriptan is a serotonin 5-HT1b/1d receptor agonist that is used for the acute treatment of migraine attacks. A new fast-disintegrating/rapid-release sumatriptan tablet (sumatriptan FDT/RRT) has been developed with the goal of speeding absorption and onset of effect compared with standard sumatriptan tablets.
▴ Bioequivalence of sumatriptan FDT/RRT tablets to standard sumatriptan tablets was established in healthy volunteers. Initial data suggest that sumatriptan FDT/RRT tablets may disintegrate faster and get emptied from the stomach faster than standard sumatriptan tablets.
▴ In a randomised, double-blind, multicentre, early intervention trial in adults with mild migraine, significantly more sumatriptan FDT/RRT 50 and 100mg recipients than placebo recipients were pain free or migraine free 2 hours after receiving study medication.
▴ Compared with placebo, pain relief was significantly greater with sumatriptan FDT/RRT 100mg at 25 and 17 minutes following administration, and with sumatriptan FDT/RRT 50mg at 50 and 30 minutes following administration, in two randomised, double-blind, multicentre trials in adults with moderate to severe migraine.
▴ Sumatriptan FDT/RRT tablets were generally well tolerated; the tolerability profile was similar to that reported for standard sumatriptan tablets in other studies.
Fußnoten
1
Trade names include Imitrex®, Imitrex DF®, Imigran Radis®, Imigran FDT®, Imigran Sprint®, Imigran Neo®, Imigran Novum®, Imigran T® and Imigran Ftab®. The use of trade names is for product identification purposes only and does not imply endorsement.
 
2
For a full list of trade names, please refer to footnote 1.
 
Literatur
1.
Zurück zum Zitat Perry CM, Markham A. Sumatriptan: an updated review of its use in migraine. Drugs 1998 Jun; 55(6): 889–922PubMedCrossRef Perry CM, Markham A. Sumatriptan: an updated review of its use in migraine. Drugs 1998 Jun; 55(6): 889–922PubMedCrossRef
2.
Zurück zum Zitat Dowson AJ, Lipscombe S, Sender J, et al. New guidelines for the management of migraine in primary care. Curr Med Res Opin 2002; 18(7): 414–39PubMedCrossRef Dowson AJ, Lipscombe S, Sender J, et al. New guidelines for the management of migraine in primary care. Curr Med Res Opin 2002; 18(7): 414–39PubMedCrossRef
3.
Zurück zum Zitat Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005 Apr; 45 Suppl. 1: S3–13PubMedCrossRef Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005 Apr; 45 Suppl. 1: S3–13PubMedCrossRef
4.
Zurück zum Zitat Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia 2004; 24 Suppl. 2: 2–7PubMedCrossRef Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia 2004; 24 Suppl. 2: 2–7PubMedCrossRef
5.
Zurück zum Zitat Nissan GR, Diamond ML. Advances in migraine treatment. J Am Osteopath Assoc 2005 Apr; 105 (4 Suppl. 2): S9–15 Nissan GR, Diamond ML. Advances in migraine treatment. J Am Osteopath Assoc 2005 Apr; 105 (4 Suppl. 2): S9–15
6.
Zurück zum Zitat Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine. CNS Drugs 2004; 18(6): 337–42PubMedCrossRef Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine. CNS Drugs 2004; 18(6): 337–42PubMedCrossRef
7.
Zurück zum Zitat Morey SS. Guidelines on migraine: part 3. Recommendations for individual drugs. Am Fam Physician 2000 Nov 1; 62(9): 2145–8, 2151PubMed Morey SS. Guidelines on migraine: part 3. Recommendations for individual drugs. Am Fam Physician 2000 Nov 1; 62(9): 2145–8, 2151PubMed
8.
Zurück zum Zitat McCrory DC, Gray RN. Oral sumatriptan for acute migraine (review). Cochrane Database Syst Rev 2003; (3): CD002915 McCrory DC, Gray RN. Oral sumatriptan for acute migraine (review). Cochrane Database Syst Rev 2003; (3): CD002915
9.
Zurück zum Zitat Walls C, Lewis A, Bullman J, et al. Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr Med Res Opin 2004 Jun; 20(6): 803–9PubMedCrossRef Walls C, Lewis A, Bullman J, et al. Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr Med Res Opin 2004 Jun; 20(6): 803–9PubMedCrossRef
10.
Zurück zum Zitat Sheftell FD, Dahlöf CGH, Brandes JL, et al. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther 2005 Apr; 27(4): 407–17PubMedCrossRef Sheftell FD, Dahlöf CGH, Brandes JL, et al. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther 2005 Apr; 27(4): 407–17PubMedCrossRef
11.
Zurück zum Zitat Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004 Jan; 55(1): 19–26PubMedCrossRef Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004 Jan; 55(1): 19–26PubMedCrossRef
12.
Zurück zum Zitat Kori SH, Sandefer EP, McDonald SA, et al. Improved disintegration and gastric emptying of sumatriptan tablets formulated with RT Technology™ [abstract no. P06.031]. Neurology 2005; 64 (6 Suppl. 1): A349. Plus poster presented at the 57th Annual Meeting of the American Academy of Neurology; 2005 Apr 9–16; Miami Beach, FL Kori SH, Sandefer EP, McDonald SA, et al. Improved disintegration and gastric emptying of sumatriptan tablets formulated with RT Technology™ [abstract no. P06.031]. Neurology 2005; 64 (6 Suppl. 1): A349. Plus poster presented at the 57th Annual Meeting of the American Academy of Neurology; 2005 Apr 9–16; Miami Beach, FL
13.
Zurück zum Zitat GlaxoSmithKline UK. Imigran Radis 50mg and 100mg tablets: UK prescribing information [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2006 Jan 27] GlaxoSmithKline UK. Imigran Radis 50mg and 100mg tablets: UK prescribing information [online]. Available from URL: http://​emc.​medicines.​org.​uk [Accessed 2006 Jan 27]
14.
Zurück zum Zitat Carpay J, Schoenen J, Ahmad F, et al. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin Ther 2004 Feb; 26(2): 214–23PubMedCrossRef Carpay J, Schoenen J, Ahmad F, et al. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin Ther 2004 Feb; 26(2): 214–23PubMedCrossRef
15.
Zurück zum Zitat Barbanti P, Carpay JA, Kwong WJ, et al. Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine. Curr Med Res Opin 2004 Dec; 20(12): 2021–9PubMedCrossRef Barbanti P, Carpay JA, Kwong WJ, et al. Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine. Curr Med Res Opin 2004 Dec; 20(12): 2021–9PubMedCrossRef
16.
Zurück zum Zitat GlaxoSmithKline. Imigran Neo® sumatriptan (succinate): prescribing information (Spain). Madrid: GlaxoSmithKline, S.A., 2004 Oct GlaxoSmithKline. Imigran Neo® sumatriptan (succinate): prescribing information (Spain). Madrid: GlaxoSmithKline, S.A., 2004 Oct
Metadaten
Titel
Sumatriptan Fast-Disintegrating/Rapid-Release Tablets
verfasst von
Marit D. Moen
Gillian M. Keating
Publikationsdatum
01.04.2006
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 6/2006
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200666060-00018

Weitere Artikel der Ausgabe 6/2006

Drugs 6/2006 Zur Ausgabe

Adis Drug Evaluation

Rituximab

Adis Drug Profile

Lubiprostone